Podcasts about Weisel

Rachel is a creative problem solver who thrives in collaborative environments. She's spent the last decade building products and leading teams, leveraging her background in design and data to bring digital and physical products to life. She is currently focused on a personal project, Happy Arranging, inspiring others to bring more joy into their lives by creating flower arrangements using grocery store flowers. On this episode, Rachel talks with Mary about her jump from working at The Metropolitan Museum of Art to working in healthcare.

Today, we're delving into the profound effects of mold exposure on the mind and body with our guest Caitlin Weisel, an Emergency & Trauma Registered Nurse. When Caitlin first began experiencing mysterious physical and neurological symptoms, it took her multiple doctors and perspectives to finally learn that she was suffering from prolonged mold exposure. Join us for this jampacked episode on exploring the impact of mold on the mind and body, detoxification tips and tricks, and the power of Somatic Release Yoga.Caitlin shares her rocky journey of experiencing intense burnout and PTSD -- and how she managed to rise above it all. Learn how Caitlin continues to champion for Somatic Release Yoga as a powerful tool for trauma healing and stress reduction. As an advocate for holistic wellness, her wealth of experience also touches on the impact of ketamine therapy and the need for reframing your inner narratives. The episode then dives into Caitlin's harrowing experience with toxic mold exposure, which subjected her to physical and mental ailments. Join us as Freddie shares his wealth of experience in terms of detecting mold in your home and looking out for mold exposure symptoms. Get to know more about the science behind detoxifying the body, and the revolutionary benefits of practices like Dynamic Neural Retraining (DNRS) and using castor oil packs.As we swap stories on the failures of our conventional healthcare system, this episode shines a spotlight on how functional medicine, biohacking, and active learning are stepping stones toward achieving your most optimal self.HIGHLIGHTS[3:20] Getting to Know Nurse Caitlyn[6:15] Burnout as an ER Nurse[10:49] Overcoming PTSD[15:25] Reframing Your Subconscious Narratives[18:10] Her Experience With Mold Exposure[24:28] Understanding the Body's Emunctory Organs[26:57] The Recurring Problem of Traditional Medicine[28:20] Checking Mold in Your Home[36:15] Helping Your Skin Detoxify[39:20] The Benefits of Castor Oil Packs[41:35] The Science Behind Dynamic Neural Retraining (DNRS)[44:35] On Gut Health and Bowel MovementsGUEST LINKSWebsite: https://www.rockroseyoga.com/Instagram: https://www.instagram.com/rockroseyogaPodcast: https://podcasts.apple.com/us/podcast/unlikely-to-apologize/id1594980979?i=1000547629816UPGRADE YOUR WELLNESSSilver Biotics Wound Healing Gel: https://bit.ly/3JnxyDDCode: BEAUTIFULLYBROKENMarion Institute BioMed Course: biologicalmedicine.orgCode: beautifullybrokenLightPathLED https://lightpathled.com/?afmc=BEAUTIFULLYBROKENCode: beautifullybrokenSTEMREGEN: https://www.stemregen.co/products/stemregen/?afmc=beautifullybrokenCode: beautifullybrokenGOT MOLD?: https://www.gotmold.com/beautifullybroken/Code: beautifullybroken10Flowpresso 3-in-1 technology: https://www.beautifullybroken.world/flowpressoMedical grade Ozone Therapy: https://lddy.no/1djnhCode: BEAUTIFULLYBROKENAquaCure Machine + Molecular HydrogenWebsite:https://eagle-research.com?ref=24931Code: beautifullybrokenDIY Home Cold Exposure: https://www.penguinchillers.com/product/beautifullybroken/My Favorite Sauna: Therasage https://bit.ly/39mTxwYCode: BEAUTIFULLYBROKENCONNECT WITH FREDDIECheck out my website and store:www.beautifullybroken.worldInstagram – https://www.instagram.com/beautifullybroken.world/YouTube: https://www.youtube.com/@BeautifullyBrokenWorld

Ep13-Art Bell-Volcanoes and Earth Changes-Dorian Weisel

Volcanoes and Earth Changes - Dorian Weisel

On this Scared of Normal episode we were fortunate enough to sit down with Charlie Weisel, a seasoned traveler who has ridden his custom-built Harley-Davidson chopper over 265,000 miles across29 countries, and through all 48 contiguous United States. Charlie didn't grow up around motorcycles, but his passion for traveling and wheels led him to explore the world on his Harley. He's constantly modifying his motorcycle and has built a close relationship with it as he's traveled the world. Charlie believes that the more remote and difficult the roads are, the greater the rewards & takes pride in not taking the easy way. From traveling across the remoteness of eastern Russia to relying on the kindness of strangers, he shares his experiences and insights into adventures on the road, the challenges, and the rewards of pushing through hard days. This episode is truly chocked full of incredible stories & perspective do yourself a favor & turn on, tune in, drop out.It's truly inspiring to sit down with someone as authentic as Charlie, he does what he does for himself & no one else; which is exactly how it should be. His grit & pride in his craft left me feeling re-energized & stoked to take on whatever challenge comes next.  _________________Learn more about Traction or purchase coffee: https://traction.coffee_________________Guest:Charlie Weisel //https://www.instagram.com/travelingch...Host:Mike Murfitt // https://instagram.com/mikemurfitt/_________________// founder note //It's truly inspiring to be in the pretense of someone as truly authentic as Charlie, he does what he does for himself & no one else; which is exactly how it should be. His grit & pride in his craft left me feeling re-energized & stoked to take on whatever challenge comes next.  Thanks for the hangs Charlie - already lookin' forward to next time! -Mike

Indoor track season is closing in on championship racing, but before gearing up for all that action we take a step back and welcome on Ben Weisel, who you may know from The Stride Report's Blue Oval Podcast. Ben and Scotty discuss Ben's background of how he got into running, why he chose Belmont, what were some of the challenges and top moments competing in the NCAA, and why Ben wants to continue in the sport now as an Analyst and Coach. Ben also debunks the myth that the Mile is better than the 1500. Contact the show: chiptimepod@gmail.com. Leave a 5-star rating on Apple or Spotify if you enjoyed. Ben's contact information: weiselracing@gmail.com (or search "WeiselRacing" on Instagram or Twitter and slide into his DMs) Shop my Favorite 100% Science-Backed Amino Acid Supplements Enter Code "CHIPTIME " To Save 30% ► aminoco.com/CHIPTIME

Charles Weisel has ridden his 10'4” chopper hundreds of thousands of miles, traveling the roads of 18 European countries, Mexico, Russia, India, and all 48 contiguous United States. Check out his Instagram here: https://www.instagram.com/travelingchopper/

Charlie is travelling the world on his chopper.  Ive been a follower and fan of his travels for a long time and was thankful to get him to join the podcast.  We did this over Instagram so please be mindful of audio.  This was a quick and short one but we squeezed in some great conversation and topics.  We will sit down again and do another. With his travels we have a lot more to discuss! Enjoy this episode! --- Support this podcast: https://anchor.fm/harley-showcase/support

Apply for 1 on 1 online coaching HERETo get more details click HEREIn this episode, I will be taking a deep dive into a topic I find interesting.Topics:-The Most Common Reason For Your Fat Loss PlateauReferences: Clark, D., Tomas, F., Withers, R. T., Chandler, C., Brinkman, M., Phillips, J., Berry, M., Ballard, F. J., & Nestel, P. (1994). Energy metabolism in free-living, ‘large-eating' and ‘small-eating' women: studies using 2H2(18)O. The British journal of nutrition, 72(1), 21–31. https://doi.org/10.1079/bjn19940006Champagne, C. M., Bray, G. A., Kurtz, A. A., Monteiro, J. B., Tucker, E., Volaufova, J., & Delany, J. P. (2002). Energy intake and energy expenditure: a controlled study comparing dietitians and non-dietitians. Journal of the American Dietetic Association, 102(10), 1428–1432. https://doi.org/10.1016/s0002-8223(02)90316-0Lafay, L., Mennen, L., Basdevant, A., Charles, M. A., Borys, J. M., Eschwège, E., & Romon, M. (2000). Does energy intake underreporting involve all kinds of food or only specific food items? Results from the Fleurbaix Laventie Ville Santé (FLVS) study. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 24(11), 1500–1506. https://doi.org/10.1038/sj.ijo.0801392Lichtman, S. W., Pisarska, K., Berman, E. R., Pestone, M., Dowling, H., Offenbacher, E., Weisel, H., Heshka, S., Matthews, D. E., & Heymsfield, S. B. (1992). Discrepancy between self-reported and actual caloric intake and exercise in obese subjects. The New England journal of medicine, 327(27), 1893–1898. https://doi.org/10.1056/NEJM199212313272701

Welcome to ShopTalk, America's first and favorite weekly motorcycle talk show. Thanks to our good friends at Dennis Kirk we come to your headspace every Sunday night at 9 PM EST with a little bit of news, some cool products, and some great people from the industry. In tonights Episode of ShopTalk we're gonna blow your mind. Chopper Charlie is checking in from Slovenia where he is in a campground for a break on his epic trip around the world on a long chopper. We are gonna find out the good the bad and the ugly. We have a tech tip on putting together CT Newman's Exhaust Fixture for building a custom exhaust with Josh Boggs of Steel City Blacksmithing. We have an event report from the Dennis Kirk Garage Build Bike Show in Daytona. As usual, all the bullshit we can fit in 90 to 120 minutes of ShopTalk.

Today I'm joined by Arch-Vorthos Loreley Weisel-Librizzi to talk about the story, writing flavor text and giving voice to New Capenna! This Episode brought to you by CoolStuffInc, Coalesce Apparel and Design, and Archidekt.

In this episode, the FReality crew discusses Moss 2 and Roblox in VR while having a chat with Max Weisel about Nock VR. *Release Date:* 19 March 2022 on https://www.youtube.com/freality/live

Barbara Peters in conversation with Sara E Johnson and Fred Weisel

When we recorded this podcast Charlie was on his way to Russia! Hear our earlier podcast HERE. Somebody wins a 100$ giftcard to LowBrowCustoms.comMotorCyleSherpa.comYouTube Link HERE for Mint 400 Video Made by Gran Teton HDDangerHEAT IT! TACK IT! WELD IT! SMACK IT!-LedSledClick Here to Become a Patron Keep fuelin my fire!!!^^^^^^^^^^^^ Patreon! Giveaways from LowbrowCustoms HeavyClothing Chemical Candy CustomsMCshopTs.com Your T-shirt of the month club. OLD SHOPS, NEW ART, and FRESH T's EVERY MONTH!!!! Only 25$ a month, sign up at MCshopTs.com Don't miss another month!!!SUPPORT EVERY LOCAL MOTORCYCLE SHOPGo to DangerDansTalkShop.com and become a Patreon Supporter for your chance to win!!! DangerDansTalkShop.comPatreonMCshopTs.comLowbrow CustomsKniveMadeByNickChemical Candy CustomsBrown's CycleHEAVY Permalink

We were able to ring in Charlie as he rides down to Florida for daytona, then on to Europe and eventually around the globe! He is a lover of the open road, you can find his writings in the likes of cycle source magazine and at www.roadsareforjourneys.com   Support the podcast by donating to our Patreon which helps us bring on more guests and build the quality of this show, at  Www.patreon.com/fastlifegarage   @simpson_motorcycle_helmets For me personally I have logged thousands of miles in Simpson's and the fit and quality is perfect for me from how I ride and how I wanna look rolling down the highway!   ⚡️www.simpsonmotorcyclehelmets.com   @houseofharley  House of Harley Davidson located in Milwaukee Wisconsin, has been my go to for Harley Davidson parts, its where I buy my bikes and get high end work done!  Head over to  www.houseofharley.com  Offer code FASTLIFE at check out saves you 13%   @Thundermaxefi I have ran these computers for years on my bikes, thundermax is the shit at keeping my bike running it's best and keeping my M8 cool with their electric fan!  ⚡️www.shoptmax.com Offer code “fastlife” for 10% off   @lexinmoto I listen to everything from music and podcasts to even audio books as I smash miles across the country with lexin!  ⚡️www.lexin-moto.com Offer code “fastlife” for 15% off   @Letriclightingco  I run letric lighting front to back on my road glide,  all of which is backed by strong warranties and are some of the best looking and producing lighting products on the market!  Www.namzcustomcycleproducts.com

A virtual event presentation by Mindy Weisel ABOUT THE EVENT: This compelling and candid memoir (AFTER: The Obligation of Beauty) by Mindy Weisel, an internationally acclaimed artist and author, traces her search for beauty in her life, which began as a child born in the Bergen-Belsen Displaced Person's Camp to parents who had survived the Auschwitz concentration camp. This is not her parents' story, rather, it is a courageous and honest portrait of her struggle to understand the black hole she was born into. Her successful journey in becoming an artist with her own voice, and an unshakable will to live with beauty, is most inspiring. By weaving an eloquent tapestry of her art, narrative, poetry and journals, Ms. Weisel offers moving insights into her life and work, especially her deep-seated conviction that beauty and love can overcome tragedy. ABOUT THE SPEAKER: Mindy Weisel, an internationally renowned artist, author and speaker, was elected into the Smithsonian Archives of American Artists in 2000. Her works are in the permanent collections of the National Museum of American Art, Oxford University, and the Israel Museum, among many other public and private collections. Weisel is the author of DAUGHTERS Of ABSENCE: Transforming a Legacy of Loss; and TOUCHING QUIET: Reflections in Solitude. She is also a member of the United States Art In Embassies Program; and the Jerusalem Biennial. Weisel, the mother of three, resided in Washington, D.C. for over forty years, where she was an Associate Professor at the Corcoran College of Art and Design (1996-2005). She received her BFA at George Washington University and did her post graduate work at American University, Washington, D.C. Weisel's extensive interviews and TV appearances are documented on her website www.mindyweisel.com. Among them, CNN, Bloomberg, Jewish Women's Archives. Currently, Mindy Weisel resides in Jerusalem Israel, with her husband. You can purchase the book here – https://www.amazon.com/AFTER-Obligation-Beauty-Mindy-Weisel/dp/1913532550/ref=sr_1_1?dchild=1&keywords=Mindy+Weisel+AFTER&qid=1631562301&sr=8-1 ABOUT THE EVENT: This compelling and candid memoir (AFTER: The Obligation of Beauty) by Mindy Weisel, an internationally acclaimed artist and author, traces her search for beauty in her life, which began as a child born in the Bergen-Belsen Displaced Person's Camp to parents who had survived the Auschwitz concentration camp. This is not her parents' story, rather, it is a courageous and honest portrait of her struggle to understand the black hole she was born into. Her successful journey in becoming an artist with her own voice, and an unshakable will to live with beauty, is most inspiring. By weaving an eloquent tapestry of her art, narrative, poetry and journals, Ms. Weisel offers moving insights into her life and work, especially her deep-seated conviction that beauty and love can overcome tragedy. -- DONATE: www.bit.ly/1NmpbsP​​​​​​​ For podcasts of VBM lectures, GO HERE: www.valleybeitmidrash.org/learning-library/ www.facebook.com/valleybeitmi...​ Become a member today, starting at just $18 per month! Click the link to see our membership options: www.valleybeitmidrash.org/become-a-member/

Learn more about the importance of regenerative agriculture from Cincinnati Zoo elephant keeper and owner of Good Shepherd Farm, Amanda!  

If you'd like access to lots more episodes without limits- support us at https://www.patreon.com/ArtBell from only $5 per month. Thank you! 1995-11-06 - Coast to Coast AM with Art Bell - Volcanoes and Earth Changes - Dorian Weisel ##Note## The episodes will only remain in this free feed for the current month. If you'd like access to lots more episodes without limits- support us at https://www.patreon.com/ArtBell from only $5 per month. Thank you!

Welcome to Times Will Tell, the weekly podcast from The Times of Israel. This week, we speak with artist Mindy Wiesel about her lifelong search for beauty in her artwork and life, amid the turmoil, pain and love of her Holocaust survivor parents. "AFTER: The Obligation of Beauty," is an unusual memoir, a hardbound, slim volume that divides Weisel's life into chapters of her artistic experience, with photos of her work, which includes paintings, glassworks and sculpture, illustrating each section. It's a work that Weisel wrote over the course of eleven years, tracing her search for beauty in her life. She was born after the Holocaust, in the Bergen-Belsen Displaced Person's Camp to parents who survived Auschwitz, and is a cousin to the late Elie Wiesel. Yet despite those complicated beginnings, the book is Weisel's own story, her struggles as a "second generation," a child of survivors. The memoir traces Weisel's lifelong journey to understand her parents' trauma into which she was born and an unshakable will to live with beauty, one that she has attempted to fulfill  her entire life. By weaving a tapestry of her art, narrative, poetry and journals, Weisel offers moving insights into her life and work, especially her deep-seated conviction that beauty and love can overcome tragedy. Weisel, her husband and children lived in Washington, DC for forty years before she moved with her husband to Jerusalem ten years ago. Her art is on permanent display at the National Museum of American Art, Oxford University and the Israel Museum, and in many public and private collections. The book is available for purchase on Amazon; Weisel will also have a solo exhibit this November at the Rosenbach Gallery in Jerusalem. Times Will Tell podcasts are available for download on iTunes, TuneIn, Pocket Casts, Stitcher, PlayerFM or wherever you get your podcasts. IMAGE: Artist Mindy Weisel in her Jerusalem home, prior to the September 2021 launch of her memoir, "After." See omnystudio.com/listener for privacy information.

#InsurTechTalk by @InsurTechLAEpisode 32Thomas Verduzco-Weisel, Director Central Europe for CoreLogic | Symbility and an active InsurTech evangelist and Gilad Shai come together on Thomas's Clubhouse "Insurance Innovation" https://www.joinclubhouse.com/club/insurance-innovation and on this channel. Surprisingly, Gilad was the interviewee. Topics:#Faliures, #Blockchain, #CVC, and flat-whites

Barbara Peters in conversation with Frederick Weisel

Dr. Mitul Gandhi, a medical oncologist specializing in hematologic malignancies at Virginia Cancer Specialists, which is part of the US Oncology Network, highlights key abstracts from the #ASCO20 Virtual Scientific Program that aim to improve outcomes for patients with multiple myeloma. Transcript ASCO Daily News: Welcome to the ASCO Daily News Podcast. I'm Geraldine Carroll, a reporter for the ASCO Daily News. I'm delighted to welcome Dr. Mitul Gandhi, a medical oncologist with Virginia Cancer Specialists, which is part of the US Oncology Network. Dr. Gandhi's clinical and research focus is in malignant hematology.   Today he will highlight key abstracts featured at the ASCO20 Virtual Scientific Program and discuss the potential of new agents and treatment approaches to improve outcomes for patients with multiple myeloma. Dr. Gandhi reports no financial conflicts of interest relating to the issues discussed in this podcast. Full disclosure is relating to all daily news podcasts can be found on our episode pages.   Dr. Gandhi, welcome to the ASCO Daily News Podcast.   Dr. Mitul Gandhi: Thank you for having me. I really appreciate the opportunity to review the abstracts from this year's meeting.   ASCO Daily News: Can you tell us about the abstracts that will likely support new standards of care?   Dr. Mitul Gandhi: So within the world of multiple myeloma, there were several exciting studies that were conducted with investigational agents that are new, and then repurposing existing agents in different lines of therapy. When reviewing this, while it may not change how we practice tomorrow, it certainly informs what may be in the very near future.   I think a representative abstract is 8500, presented by Dr. Richardson and his colleagues, and involved a novel compound CC-92480 in relapsed refractory myeloma. And this is an interesting compound, which is a Cereblon ligase modulator and a next iteration of agent based on the Revlimid and, rather, lenalidomide and pomalidomide mechanism acting on Cereblon and degrading Ikaros and Aiolos.   And this was a phase I study with a phase II expansion based on the maximally tolerated dose. And what they found were that this agent studied in heavily pretreated myeloma patients, all refractory lenalidomide, pomalidomide in the majority refractory to anti-CD38 antibodies. This drug was still able to achieve a response across several dosing cohorts.   They had a complex study design involving twice daily along with once daily dosing, and a 1.0 milligram-per-day dose was identified as a MTD. And at that dose, they found 48% of patients achieved a response, with correlative studies demonstrating degradation in Ikaros and Aiolos consistent with the mechanism of action.    And so what it tells us is that this mechanism still remains a potent avenue for exploitation in spite of progression on first- and second-rate generation compounds like lenalidomide and pomalidomide. So this informs possible changes in the future, where we would continue to use a compound like CC-92480 in spite of progression on the existing agents.   And we can see itself working in earlier lines of study and complexing with other compounds to the increased response rate. So this is something that we think will be relevant in the future if not relevant tomorrow in terms of standard of care.   ASCO Daily News: There have been substantial improvements in survival for patients with multiple myeloma in recent years, thanks to the introduction and widespread use of multiple novel agents and regimens. Are there new treatment approaches or agents in development that people should be aware of?   Dr. Mitul Gandhi: Absolutely. I think this can be viewed in a few ways. As all the listeners are well aware of and have experience with, the monoclonal antibodies on top of the existing backbone of treatment that has led to significant improvement and outcomes with relapsed refractory patients, both with daratumumab and elotuzumab.   Daratumumab, of course, being in an anti-CD38 antibody and elotuzumab targeting SLAMF7. There are next-generation antibodies on the anti-CD38 backbone, such as isatuximab. And that was studied in abstract 8508 in high-risk multiple myeloma by Dr. Weisel and colleagues from Germany.   So this particular study kind of captures what the goal is, which are moving these monoclonal antibodies higher up in the lines of therapy. So this particular trial looked at higher risk multiple myeloma, defined by chromosomal aberrations, such as deletion 17p, translocation (4;14) or (14;16), or excess copies of 1q21.   These patients received isatuximab on top of the KRd backbone, with an option for pursuing stem cell transplantation. There were 50 patients in the initially presented data -- 46 in the transplant eligible; 4 in the transplant ineligible. And one of the striking things that was identified was a 46% complete response rate in a otherwise high-risk cohort.   So this is emblematic of what the field is moving towards, which is incorporating these novel antibodies on top of an established backbone and seeing better response rate that were initially met. And as an increasing amount of data identifies achieving lower and lower myeloma burden and hopefully MRD negativity, minimal residual disease negativity, earlier on, pretending long-term, better outcomes, incorporation of these novel antibodies is one - exciting, and two - it will hopefully help inform the next generation of therapy.   Notably, these results are still preliminary phase II studies. And longer term follow up will be needed to identify if they are better than the existing outcome. Another study in that same vein is abstract 8507, presented by Dr. Zafar and his colleagues from SWOG, incorporating elotuzumab with the RVd backbone for, again, newly diagnosed, high-risk multiple myeloma.   They define high risk in a similar vein as a German group with translocation (14;16), (14;20), 17 p or gain of 1q21. And they took 103 patients, randomized them to RVd or RVd plus elotuzumab. They found at 53 months median follow up, a relative similarity in the progression-free survival. 31 months for RVd and 34 months for elo RVd with a P value of 0.449.   And there was no overall survival observed, albeit that truncated follow up. Notably, there were higher rates of response with the incorporation of elotuzumab. And so what this study validated is it's certainly using the proteasome inhibitor backbone. But maybe switching the antibody to increase response rates has, at least at this first analysis, there was no improvement in PFS.   Nonetheless, I think it's an important study, as the goal seems to be incorporating novel compounds on top of an existing backbone to improve depth of response. So these are two representative abstracts, which shows where the field is moving. And the patients that are relapsed and refractory, a slew of other studies targeting anti-BCMA are particularly exciting and relevant.   The DREAMM-6 study, abstract 8502, presented by Dr. Nooka,  used belantamab, which is an antibody drug conjugate targeting the BCMA B-cell maturation antigen conjugated to a cytotoxic payload. And in heavily pre-treated penta-refractory patients, they achieved an impressive response rate, with a clinical benefit rate of almost 80%, which is exciting, as these are patients with limited treatment options.   This is a novel mechanism of action with evidence of excellent responses, many that seem to be durable. It did have a unique toxicity profile, which is increasingly being recognized with cutaneous toxicity. So incorporation of opthalmology and identification of mitigation strategies are going to be important as more familiarity is gained.   But there are a number of further studies that are being pursued with belantamab. In context of this, there were three cellular therapy protocols also presented -- abstract 8503 by Dr. Munshi and colleagues, and abstract 8504 by Dr. Mailankody and colleagues, and abstract 8505 by Dr. Berdeja and colleagues. All three were abstracts around cellular therapy using a CAR T construct targeting BCMA with three different compounds.   And all three looked at similar patient populations with heavily pretreated patients. Abstract 8503 by Dr. Munshi looked at 140 patients penta-refractory and triple-class refractory that were treated with this compound in escalating doses. They found at the highest dose cohort at 450 times 10 to the 6 cells, an overall response rate of almost 82%, many of them durable with durability at median of 11 months.   This was associated with cytokine release storm along with some neurotoxicity, both at night, rather, at 96% and 20%, respectively-- but well managed. Similar findings were found on the other cellular products. Orvacabtagene presented by Dr. Mailankody on abstract 8504 and a Juno product in abstract 8505 by Dr. Berdeja. There was evidence of cytokine release and neurotoxicity in both. But again, with significant response rates in heavily treated patients, many of them durable. So altogether, it shows that an  extension beyond what we discussed initially, where there is next generation of compounds on existing mechanism of actions, these series of abstracts are looking at incorporation of monoclonal antibodies, improving on outcomes in first-line therapy, along with targeting BCMA through either an antibody drug conjugate or through cellular therapy, eliciting responses in very heavily pre-treated patients. Many of them are durable. But with a unique set of toxicities ranging from cutaneous to cytokine release storm.   ASCO Daily News: Dr. Gandhi, are there any other clinical trials that really stood out for you this year?   Dr. Mitul Gandhi: So a few other abstracts I think that are worth noting, with respect to the clinical trials question, I think with the data that's been presented in the abstracts we've talked about, they inform the next generation of studies as we build upon the outcomes that were presented for more mature data, longer term data, and novel combinations.   A few other studies that I think were informative -- abstract 8509, presented by Dr. Kumar and colleagues, involving venetoclax plus bortezomib and dexamethasone in relapsed refractory myeloma. This was interesting because we know that venetoclax seems to have preferential sensitivity and rearranged (11;14) patients for BCL-2 high.   And what the study found in a randomized fashion of 291 patients-- 194 to the venetoclax arm and 97 of the placebo-- in the patients that had a rearranged (11;14) translocation were felt to have BCL-2 high, median duration of PFS was not reached compared to 9.9 months in the placebo arm.   So this is an impressive targeted therapy in a subset of patients. It seems to enjoy very long-term responses in spite of being heavily pretreated with venetoclax, which is a drug that's increasingly gaining experience across a wide swath of hematologic malignancies. And so it speaks to the heterogeneity of this disease and perhaps targeting on a more genomically stratified approach with these targeted compounds.   There are a few other studies I think might be relevant for practical matters on a day-to-day basis in the clinic. One of them was 8518, presented by Dr. Ailawadhi and colleagues, regarding the use of RVd in newly diagnosed myeloma with renal impairment. As we know, many of our patients can present with myeloma-associated kidney dysfunction, whether through light-chain deposition disease or a cast nephropathy with high light-chain levels.   And there sometimes is a bit of a trepidation in administering Revlimid in this setting out of concern for toxicity in the setting of depressed GFR. They performed a retrospective analysis and found that even in patients with baseline depressed GFR ranging from less than 30 or between 30 and 60, the incorporation of lenalidomide helped achieve almost equivalent outcomes in patients compared to patients who had a preserved GFR greater than 60.   So in their transplant-ineligible patients, for example, they found a median PFS of 36 months compared to 30 months in people with and without creatinine clearance less than 60. In their transplant-eligible patients, interestingly, they found a PFS of 48 months versus 43 months in the same cohort. So this speaks to the ability to safely administer this drug in achieving nearly equivalent outcomes compared to the people who have baseline intact kidney function.   So with appropriate monitoring, modification of dosing, and attention to myelosuppression, it seems as though we should be using lenalidomide-based induction therapy, which we would otherwise would if the patient's GFR was preserved and still able to achieve long-term durable responses.   A couple of other smaller studies that I think are worth mentioning include abstract 8515, presented by Dr. Cornell and colleagues, regarding bortezomib induction in light-chain amyloidosis prior to autologous stem cell transplant. There has been some question regarding what the best induction strategy is in patients who presented with light-chain amyloid.   And so this was a retrospective analysis of the CIBMTR database. We're looking at patients who had received a bortezomib-based induction versus no induction prior to proceeding with a stem cell transplant using high-dose melphalan. And it was fairly clear in their followup that a bortezomib-based induction was associated with decreased risk of relapse within two years -- 13% in the bortezomib arm versus 22% in the patients that presented directly to transplant -- and translated into overall longer PFS as well.   So this validates the use of bortezomib in patients prior to stem cell transplantation in a niche population with amyloid. Similarly, abstract 8516, presented by Dr. Zhang and colleagues, questioned whether the incorporation of an alkyqlating agent on top of this proteasome inhibitor backbone would help in these patients with light-chain amyloid.   There has been an increased use of cyclophosphamide, bortezomib, dexamethasone induction based on smaller phase II studies. So this group looked at retrospectively a bortezomib plus an alkylating backbone versus one with bortezomib alone. And found that the overall hematologic response rate was fairly similar -- 73% in the patients that received bortezomib plus an alkylator versus 85% that did not, which was not statistically significant.   So it seems as though while there is a temptation to use the alkylator, it may not be necessary. And bortezomib alone may be sufficient. But of course, it would be on a case-by-case basis. But it adds to the body of literature regarding how to treat these patients with amyloid. So I thought those were helpful analyses in a smaller population but which may be relevant tomorrow in clinic.   ASCO Daily News: Well, thank you, Dr. Gandhi, for sharing your valuable insights on these promising developments in this field.   Dr. Mitul Gandhi: Thank you for the opportunity. I appreciate it.   ASCO Daily News: And thank you to our listeners for joining us today. If you're enjoying the content on the podcast, please take a moment to rate and review us on Apple Podcast.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Episode 142 of the 4Ever2Wheels podcast is live with Charlie Weisel. We have changed the direction of the podcast and have focused on best rides, elements that made it great and of course the route!  You can see more about Charlie on his instagram or his travel website Roads are for Journeys. You can see more […] Read more

Tom and Tony chat about E-Sports and who this might be just the thing for insurers to reach younger audiences.Show Notes:Tom on LinkedIn: https://www.linkedin.com/in/thomas-verduzco-weisel/

Ontario has an incredible group of academic physicians who help to research and develop advancements in medicine. This episode features Dr. Richard Weisel, an Academic Cardiovascular Surgeon at the Toronto General Hospital and Chair of the Innovation Fund Provincial Oversight Committee (IFPOC). For more information on the Innovation Fund and the projects funded can be found here:https://ifpoc.org/

Why should you join the Chamber of Commerce? Silverdale Chamber of Commerce President Kathleen Gordon and Government Affairs Committee Chair Connie Weisel discuss the many benefits of Chamber membership.

We talk about Elie Weisel’s message from his novel “night” and his noble price prize acceptance speech.

If only we were as good at mental math as Jack is, we wouldn't have to do retakes of things because we got our math wrong. Racetrack continues to be Erin's favorite, and if anyone has fanfiction of him and Weisel as gambling buddies, feel free to @ her on Twitter because she definitely wants to read that.

As she read Unruly Bodies, an online magazine curated by bestselling author Roxane Gay, Aden Weisel thought of visual artists who addressed some of the themes as the magazine. Inspired by the magazine, Weisel – the Exhibitions Director and Gallery Curator at Stevenson University – then curated an exhibition with the same title. She tells us more.

As she read Unruly Bodies, an online magazine curated by bestselling author Roxane Gay, Aden Weisel thought of visual artists who addressed some of the themes as the magazine. Inspired by the magazine, Weisel – the Exhibitions Director and Gallery Curator at Stevenson University – then curated an exhibition with the same title. She tells us more.

Really fun episode with Charlie Weisel of the new book “Roads are for Journeys”. Go order it in Amazon or on their site! It is an amazing book that guides you through their trip in Europe. Charlie rides a 10 foot long rigid Swedish style chopper…he has. Great story!             […] Read more

1995-11-06 - Coast to Coast AM with Art Bell - Volcanoes and Earth Changes - Dorian Weisel

Actress and improv extraordinaire, Alex Rose Weisel, joins us today to discuss how to succeed as a woman in Hollywood. You might recognize her from Two and a Half Men, Jimmy Kimmel and House of Lies just to name a few. We talk about acting, dating, comedy and most importantly what it was like working with Aaron and Austin in Hotel Du Loone.

Brady brings in Alex Rose Wiesel Actress and Comedic Improviser. We talk all things “First’s” from people eating food they brought from home on the plane to Brady’s first and last time to Thailand where he was stung by a scorpion. Alex also breaks down red flags on dates aka leave your Teva’s at home. SUBSCRIBE - SHARE- LOVE - LISTEN!!!!!Video versions of My First... available at https://tinyurl.com/y9z8h6crPodcast Website: https://www.comedypopupla.com/bradyFollow us: https://www.instagram.com/bradymatthews32https://www.instagram.com/comedypopuphttps://www.instagram.com/cpupodcasts

This episode of the podcast I interviewed Peter Weisel from Hunting Hills CC. He's a young aspiring Teaching Professional like myself. His passion for teaching is evident in this podcast and I hope you enjoy! If you enjoyed this podcast, please subscribe and leave us a 5 star rating and write a review. Connect with Peter Weisel Facebook Instagram Connect with the Podcast Facebook Instagram Twitter Matt Walter Golf Academy Thanks for listening! --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/juniorgolfblueprint/support

This episode of the podcast I interviewed Peter Weisel from Hunting Hills CC. He's a young aspiring Teaching Professional like myself. His passion for teaching is evident in this podcast and I hope you enjoy! If you enjoyed this podcast, please subscribe and leave us a 5 star rating and write a review. Connect with Peter Weisel Facebook Instagram Connect with the Podcast Facebook Instagram Twitter Matt Walter Golf Academy Thanks for listening! --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/juniorgolfblueprint/support

Rabbi, Artist, Musician Ariel Burger discusses his nearly lifelong relationship with Elie Weisel—as a sensitive, searching teenager navigating a life of Talmud and comic books; an undergraduate jostling between college and rabbinical studies; as his Teaching Assistant while pursuing a doctorate on an approach to conflict resolution based on Hasidic spirituality; and finally as a student-colleague and teacher-artist forging his own pathways of activism, identity, and the ethics and metaphysics of memory. He muses on Weisel’s highly eclectic, at times almost mystical, always insistently human approach to teaching and learning. He relates some of the powerful experiences — the “karmic burdens,” spiritual transformations, collective epiphanies, and personal paths to healing — he witnessed in the BU course Wiesel taught for 40 years. (Also: the High Holidays are coming and I can’t stop thinking about what it means that I can’t stop thinking about it.)

Thomas Weisel is the founder of Montgomery Securities, an iconic boutique investment bank that was sold to a predecessor of today's Bank of America.  Upon exiting Montgomery Securities, he started another investment bank, Thomas Weisel Partners, which was later sold to Stifel Financial, where Thomas currently is a Co-Chairman.  His success stories in business, in sport, in art, and other areas of life have one theme in common - he pushes himself extremely hard to become very competent in the subject-matter. This can be said about other successful people, but when you hear Thomas' story, you realize that he takes it to a whole new level. Visit www.TheAccentPodcast.com music: bensound-memories

  Peter Wiesel joins us for episode 164 Breaking par with Bernard Sheridan. This is Peter's second appearance and is back to discuss putting and all of the things he has been working on since the last time we saw him. 

Dr Weisel speaks with ecancer at EHA 2017 about the trial of daratumumab in triplet combinations against standard of care for relapsed/refractory multiple myeloma. After an extended followup, Dr Weisel report s a mPFS of 16.7 months compared to 7.1 months. Patients with only 1 prior treatment were among the best responders, and Dr Weisel notes the recent EMA approval of this combination as a possible course of care for any suitable patients.

Dr Weisel speaks with ecancer at EHA 2017 about the ENDEAVOR trial, a head to head comparison of bortezomib or carfilzomib with dexamethasone in relapsed/refractory multiple myeloma.

[powerpress] Helping Young Golfers To Play Their Best And Enjoy Our Great Game! Welcome to Episode 82 of The Golf Improvement Podcast!  Dedicated to bringing you useful information on custom club fitting, short game improvement, and effective practice techniques to Take YOUR Game To New Heights! Show Notes: Interview with Peter Weisel from Peter Weisel […]

  Peter is the Junior Golf Coordinator at Roanoke Country Club in Roanoke, VA. A life long athlete, Peter has been playing golf since he was in high school in New Jersey. After playing college golf for Roanoke College (Salem, VA), Peter began teaching at Roanoke Country Club. Peter is a US Kids and TPI Certified Level 2 Junior Coach who has enjoyed sharing the game of golf at clubs in New Jersey and Virginia for the past ten years. He draws from his previous athletic and competitive experiences to create a unique learning environment for students of all ages and abilities. Contact Peter - www.peterweiselgolf.com